The anticancer drug tirapazamine has antimicrobial activity against Escherichia coli, Staphylococcus aureus and Clostridium difficile

FEMS Microbiology Letters

Volumn 347, Issue 1, 2013, Pages 61-69

  Shah, Zarna ^a   Mahbuba, Raya ^a   Turcotte, Bernard ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Anaerobia; Antibiotics; Prodrug; Reductase

Indexed keywords

AMPICILLIN; BACTERIAL DNA; NORFLOXACIN; OXIDOREDUCTASE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIRAPAZAMINE;

AEROBIC CAPACITY; ANAEROBIC CAPACITY; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; CLOSTRIDIUM DIFFICILE; CONTROLLED STUDY; DNA DAMAGE; DRUG METABOLISM; ESCHERICHIA COLI; GENE DELETION; HOMOLOGOUS RECOMBINATION; LETTER; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; OXYGEN CONCENTRATION; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

BACTERIA (MICROORGANISMS); CLOSTRIDIUM DIFFICILE; ESCHERICHIA COLI; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS AUREUS;

ANAEROBIA; ANTIBIOTICS; PRODRUG; REDUCTASE;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; FLUOROQUINOLONES; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; RECOMBINATIONAL DNA REPAIR; TRIAZINES;

EID: 84883780710     PISSN: 03781097     EISSN: 15746968     Source Type: Journal    
DOI: 10.1111/1574-6968.12223     Document Type: Letter

References (31)

1. Baba T, Ara T, Hasegawa M et al. (2006) Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio collection. Mol Syst 2: 2006.0008.
2. Bancroft EA (2007) Antimicrobial resistance: it's not just for hospitals. J Am Med Assoc 298: 1803-1804.
3. Boucher HW, Talbot GH, Bradley JS et al. (2009) Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48: 1-12.
4. Brown JM & Wilson WR (2004) Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4: 437-447.
5. Cooper MA & Shlaes D (2011) Fix the antibiotics pipeline. Nature 472: 32.
6. Da Silva GJ & Mendonca N (2012) Association between antimicrobial resistance and virulence in Escherichia coli. Virulence 3: 18-28.
7. Delahoussaye YM, Evans JW & Brown JM (2001) Metabolism of tirapazamine by multiple reductases in the nucleus. Biochem Pharmacol 62: 1201-1209.
8. Denny WA & Wilson WR (2000) Tirapazamine: a bioreductive anticancer drug that exploits tumour hypoxia. Expert Opin Investig Drugs 9: 2889-2901.
9. Evans JW, Chernikova SB, Kachnic LA et al. (2008) Homologous recombination is the principal pathway for the repair of DNA damage induced by tirapazamine in mammalian cells. Cancer Res 68: 257-265.
10. German N, Malik M, Rosen JD, Drlica K & Kerns RJ (2008) Use of gyrase resistance mutants to guide selection of 8-methoxy-quinazoline-2, 4-diones. Antimicrob Agents Chemother 52: 3915-3921.
11. Ghatage P & Sabagh H (2012) Is there a role for tirapazamine in the treatment of cervical cancer? Expert Opin Drug Metab Toxicol 8: 1589-1597.
12. Graham MA, Senan S, Robin H Jr et al. (1997) Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trial. Cancer Chemother Pharmacol 40: 1-10.
13. Hay MP, Hicks KO, Pruijn FB, Pchalek K, Siim BG, Wilson WR & Denny WA (2007) Pharmacokinetic/pharmacodynamic model-guided identification of hypoxia-selective 1, 2, 4-benzotriazine 1, 4-dioxides with antitumor activity: the role of extravascular transport. J Med Chem 50: 6392-6404.
14. Hay MP, Hicks KO, Pchalek K et al. (2008) Tricyclic [1, 2, 4]triazine 1, 4-dioxides as hypoxia selective cytotoxins. J Med Chem 51: 6853-6865.
15. Hellauer K, Lesage G, Sdicu A-M & Turcotte B (2005) Large-scale analysis of genes that alter sensitivity to the anti-cancer drug tirapazamine in Saccharomyces cerevisiae. Mol Pharmacol 68: 1365-1375.
16. Institute CaLS (2007) Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria. Approved Standard, Vol. 27, 7th edn. CLSI, Wayne, PA, pp. M11-A17.
17. Klein E, Smith DL & Laxminarayan R (2007) Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg Infect Dis 13: 1840-1846.
18. Kowalczykowski SC (2000) Initiation of genetic recombination and recombination-dependent replication. Trends Biochem Sci 25: 156-164.
19. Le QT, Taira A, Budenz S et al. (2006) Mature results from a randomized phase II trial of cisplatin plus 5-fluorouracil and radiotherapy with or without tirapazamine in patients with resectable Stage IV head and neck squamous cell carcinomas. Cancer 106: 1940-1949.
20. Lloyd RG & Buckman C (1991) Overlapping functions of recD, recJ and recN provide evidence of three epistatic groups of genes in Escherichia coli recombination and DNA repair. Biochimie 73: 313-320.
21. Lofmark S, Edlund C & Nord CE (2010) Metronidazole is still the drug of choice for treatment of anaerobic infections. Clin Infect Dis 50: S16-S23.
22. Marcu L, Bezak E & Olver I (2006) Scheduling cisplatin and radiotherapy in the treatment of squamous cell carcinomas of the head and neck: a modelling approach. Phys Med Biol 51: 3625-3637.
23. Patterson AV, Saunders MP, Chinje EC, Patterson LH & Stratford IJ (1998) Enzymology of tirapazamine metabolism: a review. Anticancer Drug Des 13: 541-573.
24. von Pawel J, von Roemeling R, Gatzemeier U et al. (2000) Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. Cisplatin and tirapazamine in subjects with advanced previously untreated non-small-cell lung tumors. J Clin Oncol 18: 1351-1359.
25. Payne DJ, Gwynn MN, Holmes DJ & Pompliano DL (2007) Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 6: 29-40.
26. Peters KB & Brown JM (2002) Tirapazamine: a hypoxia-activated topoisomerase II poison. Cancer Res 62: 5248-5253.
27. Reysset G (1996) Genetics of 5-nitroimidazole resistance in bacteroides species. Anaerobe 2: 59-69.
28. Rousseau D & Harbec PS (1987) Delivery volumes of the 1- and 3-mm pins of a Cathra replicator. J Clin Microbiol 25: 1311.
29. Rupnik M, Wilcox MH & Gerding DN (2009) Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 7: 526-536.
30. Senan S, Rampling R, Graham MA et al. (1997) Phase I and pharmacokinetic study of tirapazamine (SR 4233) administered every three weeks. Clin Cancer Res 3: 31-38.
31. Xia Q, Zhang L, Zhang J, Sheng R, Yang B, He Q & Hu Y (2011) Synthesis, hypoxia-selective cytotoxicity of new 3-amino-1, 2, 4-benzotriazine-1, 4-dioxide derivatives. Eur J Med Chem 46: 919-926.